Analysts Anticipate ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) to Announce -$0.20 Earnings Per Share

Equities analysts expect ASLAN Pharmaceuticals Limited (NASDAQ:ASLNGet Rating) to announce earnings per share (EPS) of ($0.20) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ASLAN Pharmaceuticals’ earnings. ASLAN Pharmaceuticals posted earnings per share of ($0.08) in the same quarter last year, which suggests a negative year over year growth rate of 150%. The firm is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that ASLAN Pharmaceuticals will report full-year earnings of ($0.66) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.42). For the next year, analysts expect that the business will report earnings of ($0.89) per share, with EPS estimates ranging from ($1.43) to ($0.50). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for ASLAN Pharmaceuticals.

ASLAN Pharmaceuticals (NASDAQ:ASLNGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02).

Several analysts have weighed in on ASLN shares. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of ASLAN Pharmaceuticals in a report on Monday, May 23rd. Piper Sandler decreased their target price on ASLAN Pharmaceuticals from $8.00 to $3.00 and set an “overweight” rating for the company in a research report on Monday, May 23rd. Finally, Zacks Investment Research lowered ASLAN Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 30th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, ASLAN Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.19.

A number of large investors have recently added to or reduced their stakes in ASLN. CAPROCK Group Inc. bought a new stake in shares of ASLAN Pharmaceuticals during the 4th quarter worth approximately $38,000. Renaissance Technologies LLC bought a new stake in shares of ASLAN Pharmaceuticals during the 1st quarter worth approximately $64,000. GSA Capital Partners LLP bought a new stake in shares of ASLAN Pharmaceuticals during the 4th quarter worth approximately $89,000. Geode Capital Management LLC raised its stake in shares of ASLAN Pharmaceuticals by 34.5% during the 3rd quarter. Geode Capital Management LLC now owns 181,659 shares of the company’s stock worth $323,000 after purchasing an additional 46,639 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of ASLAN Pharmaceuticals by 47.2% during the 3rd quarter. Barclays PLC now owns 188,764 shares of the company’s stock worth $336,000 after purchasing an additional 60,488 shares in the last quarter. 38.65% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:ASLN traded up $0.01 on Friday, hitting $0.39. The stock had a trading volume of 306,547 shares, compared to its average volume of 194,811. The firm’s 50 day moving average price is $0.68 and its 200-day moving average price is $0.96. The company has a debt-to-equity ratio of 0.81, a quick ratio of 9.63 and a current ratio of 9.63. ASLAN Pharmaceuticals has a twelve month low of $0.38 and a twelve month high of $3.87. The company has a market capitalization of $27.42 million, a price-to-earnings ratio of -0.71 and a beta of 2.33.

About ASLAN Pharmaceuticals (Get Rating)

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions.

Read More

Get a free copy of the Zacks research report on ASLAN Pharmaceuticals (ASLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ASLAN Pharmaceuticals (NASDAQ:ASLN)

Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.